8-K: Barinthus Bio Prioritizes HBV and Celiac Programs After Positive Phase 2 Data, Reports Q2 2024 Financials

Barinthus Biotherapeutics announced its Q2 2024 financial results and a strategic shift to prioritize its hepatitis B and celiac disease programs following positive clinical trial data.

Summary

• Barinthus Biotherapeutics reported its financial results for the second quarter of 2024, highlighting a net loss of $16.9 million, or $(0.43) per share.
• The company's cash position was $117.8 million as of June 30, 2024, down from $130.0 million at the end of the previous quarter.
• The company used $12.0 million in operating activities during the quarter, primarily due to pipeline development and clinical trials, offset by a $1.4 million R&D tax credit.
• Research and development expenses totaled $11.7 million for the quarter, an increase from $11.1 million in the first quarter.
• The company has prioritized its VTP-300 program for hepatitis B and VTP-1000 program for celiac disease.
• Interim data from the HBV003 trial showed nearly 20% of participants had undetectable HBsAg, and 71% of those who discontinued NUCs remained off them.
• Interim data from the IM-PROVE II trial showed 20% of participants in the VTP-300 group had undetectable HBsAg at Week 72, compared to none in the placebo group.
• The company expects to dose the first patient in the VTP-1000 celiac disease trial in the third quarter of 2024.
• Updated data from the HBV program is expected in the fourth quarter of 2024.
• The company anticipates its current resources will fund operations into the second quarter of 2026.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical trial data and strategic prioritization, balanced with financial losses and a workforce reduction. The positive clinical data and strategic focus are encouraging, but the financial losses and workforce reduction temper the overall sentiment.

Positives

• Positive interim data from the VTP-300 HBV program showed promising results in achieving undetectable HBsAg and NUC discontinuation.
• The company is strategically prioritizing programs with the greatest potential for success and value creation.
• The company has a strong cash position of $117.8 million, expected to fund operations into the second quarter of 2026.
• The company is initiating a Phase 1 trial for VTP-1000 in celiac disease, an area with no FDA or EMA-approved treatments.
• There were no Serious Adverse Events (SAEs) or Grade 3 or 4 Adverse Events (AEs) related to treatment in the HBV trials.

Negatives

• The company reported a net loss of $16.9 million for the second quarter of 2024.
• The cash position decreased from $130.0 million to $117.8 million during the quarter.
• The company has reduced its workforce as part of its strategic pipeline prioritization.
• General and administrative expenses increased by $1.2 million compared to the previous quarter.

Risks

• The company's pipeline development activities and clinical trials are subject to risks, including potential delays.
• Interim data may not reflect final results.
• The company's ability to fund operations and access capital is subject to risks.
• Global economic uncertainty and geopolitical conflicts could impact the company's operations.
• The company's estimate of its cash runway may be incorrect.

Future Outlook

The company expects to dose the first patient in the VTP-1000 celiac disease trial in the third quarter of 2024 and announce updated data from the HBV program in the fourth quarter of 2024. The company anticipates its current resources will fund operations into the second quarter of 2026.

Management Comments

• Bill Enright, Chief Executive Officer, stated that the company is prioritizing the HBV and celiac disease programs due to their potential for success and value creation.
• Bill Enright also mentioned that the company is excited to initiate the first in human clinical trial of VTP-1000 in celiac disease.

Industry Context

The prioritization of the HBV and celiac disease programs reflects a strategic focus on areas with significant unmet medical needs. The company's approach to developing novel T cell immunotherapies aligns with the broader industry trend of exploring innovative treatments for chronic infectious diseases and autoimmune disorders.

Comparison to Industry Standards

• The reported cash burn of $12 million for the quarter is within the expected range for a clinical-stage biotech company, but the company will need to manage this carefully to extend the cash runway.
• The clinical trial results for VTP-300 in HBV are promising, with a significant percentage of patients achieving undetectable HBsAg, which is a key goal in HBV treatment. This compares favorably to other companies developing HBV therapies.
• The initiation of a Phase 1 trial for VTP-1000 in celiac disease is a significant step, as there are currently no approved treatments for this condition. This positions Barinthus Bio as a potential leader in this space.
• The company's focus on T cell immunotherapies is in line with the industry's growing interest in this approach for treating various diseases. Companies like Gilead and Vir Biotechnology are also exploring similar strategies for HBV.

Management Changes

Related Party Transactions

• The document mentions license revenue from related parties for the three and six months ended June 30, 2024 of nil (three and six months ended June 30, 2023: $0.3 million and $0.8 million, respectively).

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial data and strategic prioritization, but negatively to the reported losses and workforce reduction.
• Employees may be impacted by the workforce reduction.
• Patients with HBV and celiac disease may benefit from the company's focus on developing new treatments.
• Creditors and suppliers may be impacted by the company's financial performance.

Next Steps

• The company expects to dose the first patient in the VTP-1000 celiac disease trial in the third quarter of 2024.
• The company plans to announce updated interim data from the HBV003 and AB-729-202 trials in the fourth quarter of 2024.

Key Dates

Keywords

immunotherapeutics, hepatitis B, celiac disease, clinical trials, T cell, VTP-300, VTP-1000, biopharmaceutical, R&D, financial results